| Non-Small Cell Lung Carcinoma
Alunbrig vs Lorbrena
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Alunbrig vs Lorbrena with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLorbrena has a higher rate of injection site reactions vs Alunbrig based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lorbrena but not Alunbrig, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Alunbrig
Lorbrena
At A Glance
Oral
Once daily
ALK inhibitor
Oral
Daily
ALK inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Non-Small Cell Lung Carcinoma
Dosing
Non-Small Cell Lung Carcinoma 90 mg orally once daily for the first 7 days; then increase to 180 mg orally once daily; may be taken with or without food.
Non-Small Cell Lung Carcinoma 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity.
Contraindications
—
- Concomitant use of strong CYP3A inducers, due to the potential for serious hepatotoxicity
Adverse Reactions
Most common (>=10%) diarrhea, nausea, rash, cough, hypertension, fatigue, myalgia, headache, dyspnea, back pain, pruritus, edema, pyrexia, dizziness, pneumonia, arthralgia, constipation, bradycardia, abdominal pain, upper respiratory tract infection, peripheral neuropathy, stomatitis, vomiting, increased blood cholesterol
Serious ILD/pneumonitis, hypertension, bradycardia, visual disturbance, CPK elevation, pancreatic enzyme elevation, hepatotoxicity, hyperglycemia, photosensitivity
Most common (>=20%) Edema, peripheral neuropathy, weight gain, cognitive effects, fatigue, dyspnea, arthralgia, diarrhea, mood effects, cough
Serious Pneumonia, dyspnea, respiratory failure, cognitive effects, pyrexia
Pharmacology
Brigatinib is a tyrosine kinase inhibitor (TKI) with activity against ALK, ROS1, IGF-1R, FLT-3, and EGFR deletion and point mutations, inhibiting ALK autophosphorylation and downstream signaling proteins (STAT3, AKT, ERK1/2, S6) in ALK-positive NSCLC cell lines and xenograft models.
Lorlatinib is a kinase inhibitor with activity against ALK and ROS1, as well as multiple mutant forms of ALK including resistance mutations detected at progression on prior ALK inhibitors; antitumor activity is dose-dependent and correlates with inhibition of ALK phosphorylation.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Alunbrig
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Lorbrena
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Alunbrig
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Lorbrena
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Alunbrig
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Lorbrena
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/momo
Alunbrig SMART Free Trial ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AlunbrigView full Alunbrig profile
LorbrenaView full Lorbrena profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.